AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain ...

Novo Nordisk (NVO) closed the most recent trading day at $47.81, moving -2.35% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 1.16%. Meanwhile, the ...

GreensKeeper Asset Management, an investment management company, released its third-quarter 2025 investor letter. A copy of ...

Judges allow consolidation of vision loss lawsuits filed against Novo Nordisk and Eli Lilly over diabetes and weight loss ...

On December  15, 2025, UBS reaffirmed its Neutral (Hold) rating on NVO with an unchanged price target of DKK 295, reflecting ...

VanEck Pharmaceutical ETF is rated a Buy with stability, earnings visibility, and resilience across volatile market cycles.

Inflammatory bowel disease and elevated BMI may play causal roles in hidradenitis suppurativa, results of a Mendelian ...

U.S. drug maker Eli Lilly & Co. is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by ...

Despite market gains, Harbor Long-Term Growers ETF returned 6.90% (NAV) in Q3. Read the full report to understand key drivers ...

In this week’s edition of InnovationRx, we look at French healthtech Doctolib’s potential large secondary round, Alice ...

The U.S. pharmaceutical industry in 2025 remains one of the nation’s most dynamic and profitable economic sectors.

ENV-308 is a first-in-class, once-daily oral therapy designed for chronic weight management, emphasizing high-quality weight loss with muscle mass preservation and durable long-term maintenancePhase 1 ...